Novartis drug prevents heart attacks and strokes, per trial; Senate lawmakers unveil healthcare bill; Pfizer receives CRL for Epogen biosimilar
The FDA plans public meeting to encourage generic competition; Mylan reportedly offered rebates to six Medicaid programs; Republicans to present draft bill for Obamacare replacement
The FDA recently proposed studies designed to determine how disclosures in drug ads affect how viewers frame information.
Insurance companies balk at expensive PCSK9 inhibitors; Publicis to focus investments on AI platform; clinical trial reveals Novartis' eye drug requires less frequent injections
How Zicam proved that there is a better, more data-driven approach to buying and measuring TV advertising..
In only four months, Allergan's unbranded Facebook page for Botox has garnered 32 million brand impressions and 12,000 likes.
The FCB Health network won big this year with several campaigns, including work featuring a bra that detects breast cancer and an awareness campaign for human trafficking.
Novartis reports positive Phase-III results for Eylea competitor; AZ faces "critical transition point" in MYSTIC trial; physician shortage expected to rise
Drugmakers are increasingly facing blame from regulators, lawmakers, and the public as the list of lawsuits and investigations at the state and local levels grows.
Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.